Los Pinos Elisabet De Sells 16,928 Shares of Aura Biosciences (NASDAQ:AURA) Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Los Pinos Elisabet De sold 16,928 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $4.86, for a total transaction of $82,270.08. Following the sale, the insider owned 457,463 shares of the company’s stock, valued at approximately $2,223,270.18. This represents a 3.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Los Pinos Elisabet De also recently made the following trade(s):

• On Wednesday, October 29th, Los Pinos Elisabet De sold 9,049 shares of Aura Biosciences stock. The shares were sold at an average price of $6.35, for a total value of $57,461.15.

Aura Biosciences Price Performance

Shares of NASDAQ AURA opened at $5.48 on Thursday. The company has a market capitalization of $347.98 million, a price-to-earnings ratio of -2.82 and a beta of 0.46. Aura Biosciences, Inc. has a 1-year low of $4.34 and a 1-year high of $8.27. The business has a 50-day moving average of $5.73 and a 200-day moving average of $6.12.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.06. Research analysts expect that Aura Biosciences, Inc. will post -1.66 EPS for the current fiscal year.

Institutional Investors Weigh In On Aura Biosciences

A number of institutional investors have recently made changes to their positions in the company. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Aura Biosciences during the 1st quarter valued at approximately $137,000. Atria Investments Inc acquired a new stake in shares of Aura Biosciences during the second quarter worth $190,000. Levin Capital Strategies L.P. lifted its position in shares of Aura Biosciences by 9.9% in the 2nd quarter. Levin Capital Strategies L.P. now owns 1,495,560 shares of the company’s stock worth $9,362,000 after buying an additional 134,792 shares during the last quarter. Franklin Resources Inc. lifted its position in shares of Aura Biosciences by 5.9% in the 2nd quarter. Franklin Resources Inc. now owns 2,340,810 shares of the company’s stock worth $14,653,000 after buying an additional 130,221 shares during the last quarter. Finally, Invesco Ltd. acquired a new position in shares of Aura Biosciences in the 2nd quarter valued at about $76,000. 96.75% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on AURA shares. Evercore ISI began coverage on Aura Biosciences in a research report on Tuesday, November 25th. They set an “outperform” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Aura Biosciences in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $20.50.

Aura Biosciences Company Profile

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.